We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

This study has been terminated.
(Toxic Epidermal Necrolysis)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01568216
First Posted: April 2, 2012
Last Update Posted: July 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Amgen
  Purpose
The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment. After a run-in period on their current antipsychotic treatment, patients will be randomized to one of the four treatment arms as add-on therapy for a treatment duration of up to 3 months.

Condition Intervention Phase
Schizophrenia Drug: AMG 747 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Change from baseline to week 12 in negative symptoms, as measured by the NSA-16 total score [ Time Frame: 12 Weeks ]
    NSA-16 = 16-item Negative Symptom Assessment Scale, an efficacy scale used for the primary endpoint


Secondary Outcome Measures:
  • Response defined as a ≥ 20% decrease in the NSA-16 total score at week 12 [ Time Frame: 12 weeks ]
    NSA-16 = 16-item Negative Symptom Assessment Scale

  • Change from baseline to week 12 on the PANSS total score and Marder factor scores [ Time Frame: 12 weeks ]
    Positive and Negative Syndrome Scale (PANSS)

  • Change from baseline to week 12 on the CGI-S [ Time Frame: Week 12 ]
    Clinical Global Impression Severity Scale (CGI-S)

  • CGI-I scores at week 12 [ Time Frame: 12 weeks ]
    Clinical Global Impression Improvement (CGI-I)

  • Change on cognition battery [ Time Frame: 12 weeks ]
  • Change in personal and social functioning [ Time Frame: 12 weeks ]
  • Change on patient reported outcomes [ Time Frame: 12 weeks ]

Enrollment: 121
Study Start Date: May 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AMG 747 - Dose 1 Drug: AMG 747
Three dose levels once-daily oral administration
Experimental: AMG 747 - Dose 2 Drug: AMG 747
Three dose levels once-daily oral administration
Experimental: AMG 747 - Dose 3 Drug: AMG 747
Three dose levels once-daily oral administration
Placebo Comparator: Placebo Comparator Drug: Placebo
Once-daily oral administration

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) schizophrenia
  • Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥20
  • Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30
  • Receiving stable antipsychotic therapy for at least 8 weeks prior to screening
  • Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to screening
  • Subject has had a stable residence or living arrangement for at least 8 weeks prior to screening and the residence or living arrangement is not anticipated to change for the duration of the study
  • The subject or subject's legally acceptable representative has provided informed consent.

Exclusion Criteria:

  • Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive disorder, evidence of mental retardation by history or clinical examination or known premorbid IQ ≤ 70
  • Clinically significant suicidal ideation or suicide attempts, assaultive behavior or marked changes in mood within the 8 weeks prior to screening, or currently endorsing suicidal ideation in clinical exam
  • Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks prior to screening, or during screening
  • Substance dependence (with the exception of nicotine or caffeine dependence) within the 6 months prior to screening, or during screening
  • Planning to initiate a smoking cessation therapy or otherwise substantially modify nicotine use during the study
  • Positive urine drug test for substances of abuse (with the exception of positive screens for prescribed agents such as benzodiazepines).
  • Other criteria may apply
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01568216


  Hide Study Locations
Locations
United States, California
Research Site
Anaheim, California, United States, 92804
Research Site
Cerritos, California, United States, 90703
Research Site
Culver City, California, United States, 90230
Research Site
Garden Grove, California, United States, 92845
Research Site
Los Angeles, California, United States, 90073
Research Site
Norwalk, California, United States, 90650
Research Site
San Bernardino, California, United States, 92408
Research Site
Torrance, California, United States, 90502
United States, District of Columbia
Research Site
Washington, District of Columbia, United States, 20016
United States, Florida
Research Site
North Miami, Florida, United States, 33161
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30308
United States, Illinois
Research Site
Chicago, Illinois, United States, 60640
United States, New Jersey
Research Site
Marlton, New Jersey, United States, 08053
United States, New York
Research Site
Glen Oaks, New York, United States, 11004
Research Site
Rochester, New York, United States, 14618
United States, North Carolina
Research Site
Raleigh, North Carolina, United States, 27603
United States, Ohio
Research Site
Dayton, Ohio, United States, 45417
United States, Texas
Research Site
Houston, Texas, United States, 77008
Australia, South Australia
Research Site
Glenside, South Australia, Australia, 5065
Australia, Victoria
Research Site
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
Research Site
Mt Claremont, Western Australia, Australia, 6010
Canada, Alberta
Research Site
Calgary, Alberta, Canada, T2N 4Z6
Canada, British Columbia
Research Site
Penticton, British Columbia, Canada, V2A 4M4
Canada, Ontario
Research Site
Kingston, Ontario, Canada, K7L 4X3
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H3A 1A1
New Zealand
Research Site
Takapuna, Auckland, New Zealand, 1309
Russian Federation
Research Site
Khotkovo, Russian Federation, 141371
Research Site
Moscow, Russian Federation, 107076
Research Site
Moscow, Russian Federation, 115552
Research Site
Saint- Petersburg, Russian Federation, 192019
Research Site
Saratov, Russian Federation, 410028
Singapore
Research Site
Singapore, Singapore, 539747
Spain
Research Site
Santander, Cantabria, Spain, 39008
Research Site
Barcelona, Cataluña, Spain, 08036
Research Site
Cornellá de Llobregat, Cataluña, Spain, 08940
Research Site
L'Hospitalet de Llobregat, Cataluña, Spain, 08907
Research Site
Valencia, Comunidad Valenciana, Spain, 46010
Research Site
Madrid, Spain, 28009
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01568216     History of Changes
Other Study ID Numbers: 20101299
2011-004844-23 ( EudraCT Number )
First Submitted: February 27, 2012
First Posted: April 2, 2012
Last Update Posted: July 30, 2015
Last Verified: July 2015

Keywords provided by Amgen:
schizophrenia negative symptoms

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders